Physician profile
Michael Nacol
NPI 1114915030
$7,600.37
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,546 · 2020: $1,502 · 2021: $1,057 · 2022: $1,510 · 2023: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $787.75 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $780.15 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $772.54 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $665.00 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $663.85 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $594.56 | 2019-2023 | Otezla, Repatha, Evenity |
| Abbvie INC. | $435.88 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $361.62 | 2022-2023 | |
| Pfizer INC. | $275.28 | 2019-2023 | |
| Mylan Specialty L.P. | $207.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $202.16 | 2019-2023 | Xarelto |
| Radius Health, INC. | $188.33 | 2019-2020 | |
| Abbott Laboratories | $176.73 | 2020-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $143.02 | 2019-2023 | Veozah |
| Esperion Therapeutics, INC. | $131.15 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nacol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.